Gilead Sciences Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary)

Non-Alcoholic Steatohepatitis (NASH/MASH)

Disease Overview

Non-alcoholic steatohepatitis (NASH, now reclassified as MASH — metabolic dysfunction-associated steatohepatitis) is a progressive liver disease characterized by hepatic fat accumulation, inflammation and fibrosis that can progress to cirrhosis, hepatocellular carcinoma and liver failure. NIDDK estimates 1.5%-6.5% of US adults have MASH, with broader estimates of 9-15 million adults living with the disease and projections that MASH will become the leading indication for liver transplantation.

Competitive Landscape

At the time of the 2016 Gilead-Nimbus deal, the NASH field was crowded but lacked any approved therapy; the leading late-stage candidates were Intercept's obeticholic acid (Ocaliva, FXR agonist), Genfit's elafibranor (PPAR-α/δ), Allergan's cenicriviroc (CCR2/5) and Galmed's aramchol (SCD1). Gilead's strategy was a multi-mechanism combination, pairing the acquired ACC inhibitor NDI-010976 (later GS-0976/firsocostat) with selonsertib (ASK1) and cilofexor (FXR). FierceBiotech characterized the Nimbus deal as Gilead 'bagging an early-stage NASH drug in $1.2B' and later reported that Nimbus pocketed $200M of milestones within six months on rapid clinical advancement (fiercebiotech.com). The deal validated allosteric ACC inhibition and computational drug discovery as a platform — Endpoints later noted Nimbus's 'remarkable $400M upfront' positioned it favorably for subsequent fundraising (endpoints.news). Clinically, the Gilead NASH combination program ultimately disappointed in Phase 2/3 (Fierce: 'another swing, another miss'), and the field has since been overtaken by Madrigal's resmetirom (Rezdiffra), the first FDA-approved MASH therapy in 2024. Firsocostat is no longer in active Gilead development.